Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis

Cancer Letters

Volumn 283, Issue 2, 2009, Pages 152-158

  Singhal, Sharad S ^a   Yadav, Sushma ^a   Vatsyayan, Rit ^a   Chaudhary, Pankaj ^a   Borvak, Jozef ^a   Singhal, Jyotsana ^a   Awasthi, Sanjay ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Apoptosis; Cdc2; Doxorubicin; Drug resistance; Glutathione conjugate; RLIP76; Transport inhibition

Indexed keywords

BINDING PROTEIN; CYCLIN DEPENDENT KINASE 1; DOXORUBICIN; RAL INTERACTING PROTEIN 76; UNCLASSIFIED DRUG; ABC TRANSPORTER; ANTINEOPLASTIC ANTIBIOTIC; CDC2 PROTEIN, HUMAN; CYCLIN B; GLUTATHIONE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; LIPOSOME; RALBP1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG TRANSPORT; ENZYME PURIFICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; BIOSYNTHESIS; DRUG RESISTANCE; METABOLISM; NICK END LABELING; PHYSIOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CYCLIN B; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; GTPASE-ACTIVATING PROTEINS; HUMANS; IN SITU NICK-END LABELING; LIPOSOMES; PROTEIN TRANSPORT;

EID: 69849088365     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.03.033     Document Type: Article

References (21)

1. Galimberti S., Testi R., Guerrini F., Fazzi R., and Petrini M. The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. J. Chemother. 15 (2003) 374-379
2. Kourti M., Vavatsi N., Gombakis N., Sidi V., Tzimagiorgis G., Papageorgiou T., Koliouskas D., and Athanassiadou F. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int. J. Hematol. 86 (2007) 166-173
3. Jullien-Flores V., Dorseuil O., Romero F., Letourneur F., Saragosti S., Berger R., Tavitian A., Gacon G., and Camonis J.H. Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. J. Biol. Chem. 270 (1995) 22473-22477
4. Cantor S.B., Urano T., and Feig L.A. Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases. Mol. Cell. Biol. 15 (1995) 4578-4584
5. Park S.H., and Weinberg R.A. A putative effector of Ral has homology to Rho/Rac GTPase-activating proteins. Oncogene 11 (1995) 2349-2355
6. Rosse C., Hoste S., Offner N., Picar A., and Camonis J. RLIP76, an effector of the Ral GTPases, is a platform for cdk1 to phosphorylate Epsin during switch-off of endocytosis in mitosis. J. Biol. Chem. 278 (2003) 30597-30604
7. Awasthi S., Cheng J., Singhal S.S., Saini M.K., Pandya U., Pikula S., Pikula J., Singh S.V., Zimniak P., and Awasthi Y.C. Novel function of human RLIP76: ATP-dependent transport of glutathione-conjugates and doxorubicin. Biochemistry 39 (2000) 9327-9334
8. Awasthi S., Singhal S.S., Sharma R., Zimniak P., and Awasthi Y.C. Transport of glutathione-conjugates and chemotherapeutic drugs by RLIP76: a novel link between G-protein and tyrosine kinase signaling and drug-resistance. Int. J. Cancer 106 (2003) 635-646
9. Stuckler D., Singhal J., Singhal S.S., Yadav S., Awasthi Y.C., and Awasthi S. RLIP76 transports vinorelbine and mediates drug-resistance in non-small cell lung cancer. Cancer Res. 65 (2005) 991-998
10. Singhal S.S., Awasthi Y.C., and Awasthi S. Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res. 66 (2006) 2354-2360
11. Singhal S.S., Singhal J., Yadav S., Dwivedi S., Boor P.J., Awasthi Y.C., and Awasthi S. Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76. Cancer Res. 67 (2007) 4382-4389
12. Singhal S.S., Yadav S., Drake K., Singhal J., and Awasthi S. Hsf-1 and POB1 induce drug-sensitivity and apoptosis by inhibiting Ralbp1. J. Biol. Chem. 283 (2008) 19714-19729
13. Hu Y., and Mivechi N.F. HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multi-protein complex with HSP90 in vivo. J. Biol. Chem. 278 (2003) 17299-17306
14. Morinaka K., Koyama S., Nakashima S., Hinoi T., Okawa K., and Iwamatsu A. Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis. Oncogene 18 (1999) 5915-5922
15. Quaroni A., and Paul E.C. Cytocentrin is a Ral-binding protein involved in the assembly and function of the mitotic apparatus. J. Cell Sci. 112 (1999) 707-718
16. Golsteyn R.M. Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Lett. 217 (2005) 129-138
17. Mueller P.R., Coleman T.R., Kumagai A., and Dunphy W.G. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 270 (1995) 86-90
18. Sambrook J., Fritsch E.F., and Miniatis T. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor University (1989), Cold Spring Harbor, New York
19. Singhal S.S., Yadav S., Singhal J., Zajac E., Awasthi Y.C., and Awasthi S. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem. Pharmacol. 70 (2005) 481-488
20. Awasthi S., Singhal S.S., Singhal J., Yang Y., Zimniak P., and Awasthi Y.C. Role of RLIP76 in lung cancer doxorubicin-resistance: anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin-cytotoxicity. Int. J. Oncol. 22 (2003) 721-732
21. Cheng J., Sharma R., Yang Y., Singhal S.S., Sharma A., Saini M.K., Singh S.V., Zimniak P., Awasthi S., and Awasthi Y.C. Accelerated metabolism and exclusion of 4-HNE through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative-stress. J. Biol. Chem. 276 (2001) 41213-41223